Cargando…
Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers
OBJECTIVE: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors. METHODS: Patients were identified in the Calgary prosp...
Autores principales: | Eszlinger, Markus, Stewardson, Paul, McIntyre, John B, Box, Adrian, Khalil, Moosa, Hyrcza, Martin, Koro, Konstantin, Ruether, Dean, Wu, Jiahui, Paschke, Ralf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142806/ https://www.ncbi.nlm.nih.gov/pubmed/34981751 http://dx.doi.org/10.1530/ETJ-21-0061 |
Ejemplares similares
-
Activation of mitogen-activated protein kinase signaling and development of papillary thyroid carcinoma in thyroid-stimulating hormone receptor D633H knockin mice
por: Eszlinger, Markus, et al.
Publicado: (2023) -
A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes
por: Schubert, Laura, et al.
Publicado: (2023) -
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020) -
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020) -
Real-World Experience of NTRK Fusion–Positive Thyroid Cancer
por: Park, Jong Chul, et al.
Publicado: (2022)